In ovo chorioallantoic membrane assay as a xenograft model for pediatric rhabdomyosarcoma

2022 Fiscal Year Final Research Report

• Project/Area Number: 20K08187
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 52050:Embryonic medicine and pediatrics-related
• Research Institution: Kyoto Prefectural University of Medicine
• Principal Investigator: Kikuchi Ken 京都府立医科大学, 医学(系)研究科(研究院), 特任講師 (40453104)
• Co-Investigator(Kenkyū-buntansha): 柳生 茂希 京都府立医科大学, 医学(系)研究科(研究院), 助教 (10572547) ; 吉田 秀樹 京都府立医科大学, 医学(系)研究科(研究院), 助教 (10643546) ; 家原 知子 京都府立医科大学, 医学(系)研究科(研究院), 教授 (20285266)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Keywords: CAMアッセイ / 鶏卵漿尿膜 / 横紋筋肉腫 / 小児がん

Outline of Final Research Achievements

Immunodeficient mouse-derived xenograft models have been widely used as therapeutic models in the development of precision medicine; however, these models have some limitations. The chorioallantoic membrane (CAM) assay, which uses the extraembryonic membrane of fertilized chicken eggs, has many advantages over mouse models, mainly due to high vascularization and immature immune system. In the field of pediatric cancer, including rhabdomyosarcoma (RMS), treatment strategies based on patient genetic backgrounds have not been adequately developed because of the rarity and diversity. The present study aimed to examine the feasibility of using the CAM assay as a novel therapeutic model in the development of precision medicine approaches for treating pediatric cancer.

Free Research Field

小児がん

Academic Significance and Societal Importance of the Research Achievements

横紋筋肉腫細胞株のCAM上における3次元的な組織構築を確認し、CAM assayのプロトコールを確立した。さらにCAM上でのVCRの横紋筋肉腫細胞株に対する抗腫瘍効果が示され、治療モデルとしても有用性であることを確認した。
個々の患者の腫瘍遺伝学的な背景に着眼した治療法の開発が未だ充分でない小児がんにおいて、CAM assay を用いた治療モデルの確立は患者特異的な分子標的薬によるプレシジョン医療の開発につながり、難治性の小児がんの新しい治療方法の開発に寄与すると期待できる。